CN106093432A - Based on joint-detection FGF1, the kit for breast cancer of FGF10 and IL6 - Google Patents

Based on joint-detection FGF1, the kit for breast cancer of FGF10 and IL6 Download PDF

Info

Publication number
CN106093432A
CN106093432A CN201610412943.4A CN201610412943A CN106093432A CN 106093432 A CN106093432 A CN 106093432A CN 201610412943 A CN201610412943 A CN 201610412943A CN 106093432 A CN106093432 A CN 106093432A
Authority
CN
China
Prior art keywords
fgf10
fgf1
breast cancer
antibody
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610412943.4A
Other languages
Chinese (zh)
Inventor
王团老
胡修永
洪万进
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen University
Original Assignee
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen University filed Critical Xiamen University
Priority to CN201610412943.4A priority Critical patent/CN106093432A/en
Publication of CN106093432A publication Critical patent/CN106093432A/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a kind of based on joint-detection fibroblast growth factor FGF1, FGF10 and the kit for breast cancer of interleukin I L6, belongs to protein detection field.Described kit for breast cancer includes detection by quantitative FGF1, FGF10 and the reagent of interleukin I L6.The present invention is also claimed the preparation method of described test kit.Use test kit of the present invention to carry out breast carcinoma clinical diagnosis, have easy to operate, cost is relatively low, specificity and the advantage such as accuracy is good.

Description

Based on joint-detection FGF1, the kit for breast cancer of FGF10 and IL6
Technical field
The invention belongs to Protein Detection field, be specifically related to a kind of based on joint-detection FGF1, the mammary gland of FGF10 and IL6 Cancer diagnostic kit.
Background technology
Female mammary gland is made up of skin, fibrous tissue, corpus mamma and fat, and breast carcinoma is to occur on mammary gland gland The malignant tumor of skin tissue.Whole world breast cancer incidence starts the most in rising trend from late 1970s.8 woman of the U.S. Female the most just has 1 people and suffers from breast cancer.China is not the country occurred frequently of breast carcinoma, but unsuitable optimistic, China's breast carcinoma in recent years The growth rate of sickness rate but exceeds national 1~2 percentage point occurred frequently.According to National Cancer Center and Ministry of Public Health prevention and control of diseases The pathogenesis of breast carcinoma data in 2009 that office announces for 2012 show: tumor registration area, whole nation breast cancer incidence occupies women and dislikes The 1st of property tumor, female mammary gland cancer morbidity (rough and careless) whole nation adds up to 42.55/10 ten thousand, and city is 51.91/10 ten thousand, agriculture Village is 23.12/10 ten thousand.Breast carcinoma has become the great public health problem of current social.
Fibroblast growth factor (fibroblast growth factor 1, FGF1) is the egg of a 16.0KD In vain, in FGF1 from FGFs family, other members are different, secrete under stressed condition.Its biological function is quite extensive, The aspects such as generation, angiogenesis, tissue and allelotaxis, wound healing and the hemopoietic in tumor suffer from important work With.On the level of cell, can with the differentiation of regulating cell, grow, migrate, breed and the survival rate of different cell.And FGF1 not only can be by the receptor transmission signal of cell surface and enters intracellular, it is also possible to enter intracellular through cell membrane Wave effect.
Fibroblast growth factor-10 (fibroblast growth factor 10, FGF10) is a kind of alkalescence egg In vain, it is a member in FGF7 subfamily, with FGF7, there is homology highly, also referred to as keratinocyte growth factor 2 (KGF2).Most start to separate in the interstitial lung of Mus, be called the somatomedin coming from interstitial.The FGF10 of human body contains 84-246 amino acid residue, is extracellular space albumen, and the FGF10 of restructuring contains 170 amino acid residues, and size exists 19.3KD.The place of internal expression FGF10 mainly has: grow up organ and embryonic stromal cell, the epithelial cells such as liver, intestinal, lung And fibroblast.Its effect is mainly: the formation of histoorgan is grown;The reparation of tissue;Wound healing;Fetal development; The aspects such as angiogenesis.Its relation with breast carcinoma having also is in the aspect of cell, not evidence suggests its with The clinical state of an illness is relevant.
Interleukin-6 (interleukin-6, IL6) is the polyfunctional glycoprotein of a 30KD.The thinnest by T Born of the same parents, B cell, endotheliocyte, fibroblast, macrophage and epithelial cells produce.It participates in and injured and inflammation Relevant acute reaction regulation and control.Interleukin 6 is immunoreation, hemopoietic system, and a multi-functional regulatory factor of acute reaction, Have been reported that it can regulate cell proliferation.IL6 promotes hematopoietic cell, horn cell, myeloma/plasmocytoma, and card ripple The propagation of western sarcoma cell, but it but suppresses M1 bone marrow leukemia cells, melanoma cells in early days and pulmonary carcinoma, breast carcinoma are thin The increment of born of the same parents.
Breast cancer diagnosis mark commonly used in the prior art has CEA (carcinoembryonic antigen), CA153 etc., and these are not the most breasts Adenocarcinoma Specific marker, lacks specificity in breast cancer diagnosis.The present invention is based on joint-detection FGF1, FGF10 and Bai Jie Element IL6, improves specificity and the accuracy rate of breast cancer diagnosis, and this area there is not yet this type of report.
Still need and develop beyond CEA, CA153 in this area, more marks that can be used for Diagnosis of Breast cancer and test kit, With abundant breast carcinoma clinical diagnosis index, increase optional space.
Summary of the invention
Can be by the few limitation of index and deficiency based on this area breast cancer diagnosis as above, the present invention provides a kind of complete New breast cancer diagnosis method: simultaneously with FGF1, FGF10 and IL6 for detecting the kit for breast cancer of mark.
Technical scheme is as follows:
A kind of kit for breast cancer, it is characterised in that include the examination of quantitative joint-detection FGF1, FGF10 and IL6 Agent.
Described reagent refers to, the antibody of FGF1, FGF10 and IL6.
Described antibody is mouse monoclonal antibody or the rabbit polyclonal antibody of FGF1, FGF10 and IL6.
The working concentration scope of described antibody: 0.1 μ g/ml-1.0 μ g/ml.
Described kit for breast cancer, also includes the conventional reagent used by elisa.
The antibody of FGF1, FGF10 and IL6 purposes in terms of preparation kit for breast cancer.
The preparation method of a kind of kit for breast cancer, it is characterised in that the reagent assembling described test kit includes The antibody of FGF1, FGF10 and IL6;And/or
The antibody of FGF1, FGF10 and IL6 it is placed with in the packing box indicating breast cancer diagnosis purposes.
Described antibody is FGF1, FGF10 and IL6 mouse monoclonal antibody or rabbit polyclonal antibody.
The concentration range of described antibody: 0.1 μ g/ml-1.0 μ g/ml.
Assemble the conventional reagent also included in the reagent of described test kit used by elisa;And/or
The conventional reagent used by elisa also it is placed with in the packing box indicating breast cancer diagnosis purposes.
The present invention is claimed a kind of kit for breast cancer, is characterized in, including associating detection by quantitative FGF1, The reagent of FGF10 and IL6.The present invention in a creative way simultaneously with FGF1, FGF10 and IL6 as the mark of breast cancer diagnosis, and And by a large amount of clinical blood examinations, demonstrate FGF1, FGF10 and IL6 concentration in blood and characterizing breast carcinoma generation side The dependency in face, and further by carrying out contrasting with existing conventional mark CEA it was confirmed FGF1, FGF10 and IL6 combination Accuracy in terms of clinical diagnosis breast carcinoma may be up to 90%.
In some specific embodiments of the present invention, described reagent is the antibody of FGF1, FGF10 and IL6.This area can be used Have much in detection by quantitative FGF1, the method for FGF10 and IL6 and reagent, be not limited in the embodiment of the present invention employing ELISA method and the reagent used thereof, it is also possible to be the reagent of detected by Western blot and employing thereof, or other conventional albumen Detection method.Under the enlightenment of the present invention, those skilled in the art other means can be used FGF1, the FGF10 in blood sample and IL6 concentration carries out detection by quantitative.Therefore, include in the test kit for Diagnosis of Breast cancer any detection by quantitative FGF1, The reagent of FGF10 and IL6, each falls within protection scope of the present invention.
In further embodiment of the present invention, described antibody is mouse monoclonal antibody or the rabbit of FGF1, FGF10 and IL6 Polyclonal antibody, the most commercially obtains.This antibody is used to be advantageous in that: high specificity, excellent adsorption, combination rate High.
In some preferred embodiments of the present invention, the working concentration of described antibody is: 0.1 μ g/ml-1.0 μ g/ml.This Skilled person knows, and when antibody antigen combines, either antibody or antigen, the space conformation of molecule all can occur necessarily The change of degree, thus affect intermolecular further combined with, coupling or absorption, therefore, antigen concentration is stable in the sample In the case of, the working concentration of antibody controlled well is particularly important, and antibody concentration is the highest, is likely to result in non-specific binding; Antibody concentration is the lowest, is likely to result in joint efficiency low;The highest or the lowest all can affect the accurate of FGF10 Concentration Testing result Property.In order to ensure the accuracy of specificity, joint efficiency and testing result that antigen-antibody combines, the present invention specially probes into The working concentration of FGF10 antibody, finds that when concentration is in 0.1 μ g/ml-1.0 this scope of μ g/ml, joint efficiency is the highest, knot Fruit is the most accurate.
For ensureing the integrity degree of test kit, the described test kit in other preferred embodiments of the present invention also includes enzyme Conventional reagent used by linked immunosorbent adsorption test.Described conventional reagent includes: 96/48 orifice plate enzyme mark detection plate or 8 holes, hole/12 are micro- Orifice plate bar, tmb substrate nitrite ion, cleaning mixture, stop buffer, diluent.Use these conventional reagent, with the antibody one of above-mentioned concentration Rise and FGF1, FGF10 and IL6 concentration in blood sample is detected, and then whether be diagnosed to be clinical individual corresponding to sample Suffers from breast carcinoma.
The present invention is also claimed FGF1, FGF10 and IL6 purposes in terms of preparation kit for breast cancer.
When some national patent methods allow, the present invention is also claimed: FGF1, FGF10 and IL6 and/or institute State test kit purposes in terms of breast carcinoma clinical diagnosis.When in certain blood sample, the concentration of the FGF1 of detection is higher than 100pg/mL, and When the concentration of FGF10 and IL6 is above 300pg/mL, illustrates that the clinical individual that this blood sample is corresponding suffers from breast carcinoma, otherwise be then Optimum or healthy.
The present invention is also claimed the preparation method of a kind of kit for breast cancer, it is characterised in that assemble described examination The reagent of agent box includes the antibody of FGF1, FGF10 and IL6;And/or, put in the packing box indicating breast cancer diagnosis purposes It is equipped with the antibody of FGF1, FGF10 and IL6.
Further, assemble in the reagent of described test kit and also include the conventional reagent used by elisa; And/or, in the packing box indicating breast cancer diagnosis purposes, also it is placed with the conventional reagent used by elisa.This Field can be used for detection by quantitative FGF1, the method for FGF10 and IL6 and reagent to be had a lot, and is only limitted in the embodiment of the present invention adopt ELISA method and the reagent that used.Under the enlightenment of the present invention, those skilled in the art can use other means pair FGF1, FGF10 and IL6 concentration in blood sample carries out detection by quantitative.Therefore, use in kit for breast cancer preparation process Any detection by quantitative FGF1, the reagent of FGF10 and IL6, or put in any packing box indicating breast cancer diagnosis purposes appoint What detection by quantitative FGF1, the reagent of FGF10 and IL6, each falls within protection scope of the present invention.
Use FGF1, FGF10 and IL6 and/or test kit of the present invention to carry out breast cancer diagnosis, there is operation side The advantages such as just, cost is relatively low, accuracy is good.Meanwhile, the foundation of the present invention also provides new diagnosis for breast cancer diagnosis field Mark, has widened the optional space of diagnosis index.
Accompanying drawing explanation
Fig. 1 serum sample detects the concentration of FGF10.
Fig. 2 serum sample detects FGF1.
Fig. 3 serum sample detects IL6.
Detailed description of the invention
Below in conjunction with specific embodiment, present disclosure is described in further detail, but does not limit this with this Bright protection domain.Reagent used in following example and material, if no special instructions, the most commercially available;Experimental procedure If no special instructions, this area routine operation it is.
Biological material source
Human blood sample used in the embodiment of the present invention comes from the first Affiliated Hospital of Xiamen University.
Embodiment 1, the selection of mark of the present invention and checking
What the detection of FGF10 was used is the ELISA kit of Uscn company.From Fig. 1, we can be evident that three The difference existed between group sample, dense in 104-135pg/ml, carcinoid serum of the serum FGF10 concentration of healthy person Degree is between 158-208pg/ml, and the concentration in the serum of malignant tumor is at 318-575pg/ml.Statistical analysis shows optimum vs Pernicious P=0.004 < 0.05, < 0.05 has significant difference to pernicious vs health P=0.0121.
Embodiment 2, test kit of the present invention and preparation thereof
The present embodiment provides a kind of kit for breast cancer, and it includes detection by quantitative fiber mother cell growth factor 10 Reagent.
Specifically, described reagent is the antibody of fiber mother cell growth factor 10.
Further, described kit for breast cancer also includes the conventional reagent used by elisa.
The present embodiment also provides for the preparation method of a kind of breast disease diagnosis test kit, comprises the steps: fibroblast The antibody of somatomedin 10 is assembled in described test kit;And/or
The antibody of fiber mother cell growth factor 10 it is placed with in the packing box indicating breast cancer diagnosis purposes.
Described step farther includes: assembles in the reagent of described test kit and also includes used by elisa Conventional reagent;And/or
The conventional reagent used by elisa also it is placed with in the packing box indicating breast cancer diagnosis purposes.
Specifically, antibody recited above is preferably the mouse monoclonal antibody of FGF1, FGF10 and IL6 or rabbit polyclonal resists Body.
The working concentration of described antibody preferably employs following scope: 0.1 μ g/ml-1.0 μ g/ml.
Embodiment 3, test kit of the present invention is used to carry out breast cancer diagnosis
As shown in Figure 1-Figure 3, by IL6, IL9, IL21 in the serum sample of healthy, optimum, pernicious three groups of detection, The concentration of FGF1, FGF10, FGF14, finally we have chosen and can detect and pernicious patient in major part sample And having the IL6 of significant difference between normal healthy controls group, FGF1, FGF10 are as the mark of Diagnosis of Breast cancer.Additionally we go back In serum, have detected the most approved tumor markers CEA now show as positive control, data, at detection CEA quilt Be defined as No. 1 of breast carcinoma, No. 545400, No. 50, in the sample of No. 48, its FGF1, FGF10 or IL6 concentration is also suitable High.And No. 39 be shown as in normal range in CEA concentration, No. 45, No. 494969, No. 349922 samples, by us Detection IL6, one or two therein of FGF1, FGF10 are also above normal person's.The breast cancer patients of article report has The sample CEA concentration of 60% is higher than normal value.We are higher than concentration value in the testing result of three kinds of secretory proteins healthy and good Property group obviously calculate as positive, result display coincidence rate is at least more than 73.3%.We are also by secretion egg White IL6, FGF1 and FGF10 carry out joint-detection, compare and the coincidence rate of CEA diagnosis, find IL6, FGF1 and FGF10 three Joint-detection, can obtain the accuracy rate of higher breast cancer diagnosis, and up to 90%.And then also provide for a kind of based on IL6, FGF1 and The breast cancer diagnosis method of FGF10 triple combination detection, feature is, if the concentration of FGF1 is higher than 100pg/mL in blood sample, and When the concentration of FGF10 and IL6 is above 300pg/mL, then the clinical individual that this blood sample is corresponding can be diagnosed as breast carcinoma, otherwise It is then optimum or healthy.

Claims (10)

1. a kit for breast cancer, it is characterised in that include the reagent of quantitative joint-detection FGF1, FGF10 and IL6.
Kit for breast cancer the most according to claim 1, it is characterised in that described reagent refers to, FGF1, FGF10 and The antibody of IL6.
Kit for breast cancer the most according to claim 2, it is characterised in that described antibody be FGF1, FGF10 and The mouse monoclonal antibody of IL6 or rabbit polyclonal antibody.
Kit for breast cancer the most according to claim 3, it is characterised in that the working concentration scope of described antibody: 0.1μg/ml-1.0μg/ml。
5. according to the kit for breast cancer described in claim 1-4, it is characterised in that also include elisa Conventional reagent used.
6. the antibody of FGF1, FGF10 and IL6 purposes in terms of preparation kit for breast cancer.
7. the preparation method of a kit for breast cancer, it is characterised in that the reagent assembling described test kit includes The antibody of FGF1, FGF10 and IL6;And/or be placed with in the packing box indicating breast cancer diagnosis purposes FGF1, FGF10 and The antibody of IL6.
Preparation method the most according to claim 7, it is characterised in that described antibody is FGF1, FGF10 and IL6 Mus Dan Ke Grand antibody or rabbit polyclonal antibody.
Preparation method the most according to claim 8, it is characterised in that the concentration range of described antibody: 0.1 μ g/ml-1.0 μ g/ml。
10. according to the arbitrary described preparation method of claim 7-9, it is characterised in that assemble in the reagent of described test kit and go back Including the conventional reagent used by elisa;And/or also place in the packing box indicating breast cancer diagnosis purposes There is the conventional reagent used by elisa.
CN201610412943.4A 2016-06-13 2016-06-13 Based on joint-detection FGF1, the kit for breast cancer of FGF10 and IL6 Pending CN106093432A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610412943.4A CN106093432A (en) 2016-06-13 2016-06-13 Based on joint-detection FGF1, the kit for breast cancer of FGF10 and IL6

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610412943.4A CN106093432A (en) 2016-06-13 2016-06-13 Based on joint-detection FGF1, the kit for breast cancer of FGF10 and IL6

Publications (1)

Publication Number Publication Date
CN106093432A true CN106093432A (en) 2016-11-09

Family

ID=57845651

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610412943.4A Pending CN106093432A (en) 2016-06-13 2016-06-13 Based on joint-detection FGF1, the kit for breast cancer of FGF10 and IL6

Country Status (1)

Country Link
CN (1) CN106093432A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108535494A (en) * 2018-06-29 2018-09-14 湖南师范大学 A kind of IL-6ELISA detection kits and its application method

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102375064A (en) * 2010-08-26 2012-03-14 杭州华得森生物技术有限公司 In-vitro diagnostic kit for detecting HMGA2 (High Mobility Group A) content with enzyme-linked immuno sorbent assay
WO2012077139A1 (en) * 2010-12-06 2012-06-14 Thd S.P.A. Method for the diagnosis of a carcinoma and uses thereof
CN104345154A (en) * 2014-08-22 2015-02-11 北京蛋白质组研究中心 Double-antibody sandwich kit for detecting multi-tumor relevant 'polypeptide-protein combination type marker'
US20150160221A1 (en) * 2012-01-09 2015-06-11 Suzhou Microdiag Biomedicine Co., Ltd Biomarkers for breast cancer predictions and diagnoses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102375064A (en) * 2010-08-26 2012-03-14 杭州华得森生物技术有限公司 In-vitro diagnostic kit for detecting HMGA2 (High Mobility Group A) content with enzyme-linked immuno sorbent assay
WO2012077139A1 (en) * 2010-12-06 2012-06-14 Thd S.P.A. Method for the diagnosis of a carcinoma and uses thereof
US20150160221A1 (en) * 2012-01-09 2015-06-11 Suzhou Microdiag Biomedicine Co., Ltd Biomarkers for breast cancer predictions and diagnoses
CN104345154A (en) * 2014-08-22 2015-02-11 北京蛋白质组研究中心 Double-antibody sandwich kit for detecting multi-tumor relevant 'polypeptide-protein combination type marker'

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
VASSILIKI THEODOROU ET AL.: "Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas", 《ONCOGENE》 *
漆起贵 等: "CCL18、IL-6及TNF-α在乳腺癌患者血清中表达水平关系的探讨", 《重庆医学》 *
牟成金 等: "FGF-1在乳腺癌中的表达与微血管生成的关系", 《华西医学》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108535494A (en) * 2018-06-29 2018-09-14 湖南师范大学 A kind of IL-6ELISA detection kits and its application method

Similar Documents

Publication Publication Date Title
CN102209899B (en) Pacap as a marker for cancer
CN106248940B (en) The system of multi objective Combining diagnosis oophoroma and/or the malignant tumour of non-ovary origin
CN104395757A (en) Multiple biomarker sets for breast cancer diagnosis, detection method therefor, and breast cancer diagnostic kit comprising antibody against same
Sheen-Chen et al. Circulating soluble Fas in patients with breast cancer
CN103941021B (en) Kit for detecting interleukin-6 and method for detecting interleukin-6 for non-diagnostic purpose
CN109270276A (en) The urine protein marker and its diagnostic uses of oophoroma
Reis et al. Biomarkers of pelvic endometriosis
CN103923212A (en) EHD2 antibody and application of EHD2 antibody to preparation of immunohistochemical detection reagent for breast cancer
CN103207277B (en) ELISA test kit of human-derived soluble CD74 protein and detection method thereof
CN106093432A (en) Based on joint-detection FGF1, the kit for breast cancer of FGF10 and IL6
CN107014992B (en) A kind of foundation of quantitative detection human blood type antibody concentration method
CN102803968A (en) Esophageal cancer marker
CN107167604A (en) Applications of the FLOT1 in as oophoroma biomarker
CN109085355A (en) Serum protein markers combine the application in screening lung cancer and diagnosis and treatment
Itagaki et al. Relationship between the serum cancer antigen 125 level and the weight of surgically enucleated adenomyosis
CN116087522A (en) Pancreatic cancer tumor molecular marker TNK2 and detection kit and application thereof
JPH07159402A (en) Iv type collagenase measuring method
CN108414742A (en) Pepsinogen I and pepsinogen I I combined detection kits and preparation method thereof and detection method
CN104422763A (en) Use of antigen group in preparation of disease diagnosis kit and kit
CN108700594A (en) Biomarker of polycystic kidney disease and application thereof
CN107271672A (en) Applications of the excretion body p ERK in diagnosis of colorectal carcinoma product is prepared
CN210243668U (en) Test piece for rapidly and quantitatively detecting tissue cell protein
Poh et al. Prostate-specific antigen in breast disease
CN114324869A (en) Joint inspection kit for detecting breast cancer and application thereof
Mula-Abed et al. A rare case of adrenal pheochromocytoma with unusual clinical and biochemical presentation: A case report and literature review

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161109